FindTrial
Sign In

Microneedling Versus Carboxytherapy in Stria Distensae Rubra

Microneedling Versus Carboxytherapy Either With or Without Platelet Rich Plasma in Treating Stria Distensae Rubra

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07001644
Enrollment
50
Registered
2025-06-03
Start date
2022-10-01
Completion date
2025-12-31
Last updated
2025-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Striae Distensae

Keywords

striae distensae, striae rubra, microneedling, carboxytherapy

Brief summary

The aim of this study is to evaluate and compare the efficacy and safety of microneedling and carboxytherapy either with or without platelet-rich plasma in the treatment of striae distensae rubra.

Interventions

DEVICEmicroneedling

microneedling with topical application of PRP on one side of abdomen and microneedling only on the other side.

DEVICECarboxytherapy

carboxytherapy with intradermal injection of PRP on one side of abdomen and carboxytherapy only on the other side.

Sponsors

Alexandria University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Female patients. * Age ranging from 18-45 years old. * Fitzpatrick skin type III-IV. * Striae distensae rubra on the abdomen (bilateral and more or less symmetrical).

Exclusion criteria

* Patients taking immunosuppressants or having any disease affecting wound healing including diabetes. * Patients receiving systemic glucocorticoids for chronic health conditions. * Patients with chronic dermatologic diseases such as psoriasis and vitiligo. * Pregnant and lactating females. * Patients with a tendency for keloid formation. * Patients with endocrine disturbance. * Patients with autoimmune diseases, systemic diseases such as severe anemia, respiratory, cardiac, renal or liver disorder. * Patients with bleeding and coagulation disorders. * Patients who received any form of treatment for their SD in the past 6 months.

Design outcomes

Primary

MeasureTime frameDescription
Reduction in the size of the stria distensae rubragroup I: six sessions over 18 weeks , group II: 6 sessions over 12 weeks, followed in both groups by three months of follow upwill be assessed by digital photography, actual measurement of the stria before and after treatment, and objective assessment of the percent of improvement

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026